Patents by Inventor Zhaolu Zhu

Zhaolu Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pregabalin sustained release composition and method for preparing the same
    Patent number: 11938222
    Abstract: The present application relates to a pregabalin sustained release composition, comprising: (a) an active ingredient; (b) a matrix-forming agent; (c) a swelling agent; (d) a gelling agent; and optionally a filler. The pregabalin sustained release composition provided in the present application can rapidly swell in volume when exposed to aqueous medium until exceeding the dimeter of human gastric pyloric (13 mm). It thereby prolongs the gastric emptying time to increase the retention time of pregabalin in the stomach and enhances absorption of pregabalin in the small intestine and ascending colon. Moreover, the pregabalin sustained release composition provided herein achieves a sustained release for 24 h, which allows QD (once a day) administration, reduces administration number, and improves patient compliance.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: March 26, 2024
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Zhaolu Zhu, Yun Wu, Di Lu, Yanping Zhao, Liying Zhou, Yanan Liu
  • PREGABALIN SUSTAINED RELEASE COMPOSITION AND METHOD FOR PREPARING THE SAME
    Publication number: 20210369621
    Abstract: The present application relates to a pregabalin sustained release composition, comprising: (a) an active ingredient; (b) a matrix-forming agent; (c) a swelling agent; (d) a gelling agent; and optionally a filler. The pregabalin sustained release composition provided in the present application can rapidly swell in volume when exposed to aqueous medium until exceeding the diameter of human gastric pyloric (13 mm). It thereby prolongs the gastric emptying time to increase the retention time of pregabalin in the stomach and enhances absorption of pregabalin in the small intestine and ascending colon. Moreover, the pregabalin sustained release composition provided herein achieves a sustained release for 24 h, which allows QD (once a day) administration, reduces administration number, and improves patient compliance.
    Type: Application
    Filed: June 12, 2019
    Publication date: December 2, 2021
    Applicant: Beijing Tide Pharmaceutical Co., Ltd.
    Inventors: Zhaolu Zhu, Yun Wu, Di Lu, Yanping Zhao, Liying Zhou, Yanan Liu